Bio-Rad Laboratories, Inc. Class A Common Stock vs CDW Corp. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $352.85 (market cap $9.43B), while CDW Corp. trades at $133.4 (market cap $16.92B). The key difference: CDW Corp. is the larger of the two by market cap, and CDW Corp. pays a 1.86% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | CDW | |
|---|---|---|
Market Cap | $9.43B | $16.92B |
Sector | Health | Technology |
52-Week High | $356.25 | $170.77 |
52-Week Low | $241.71 | $99.30 |
Enterprise Value | $9.18B | $22.52B |
Dividend Yield | — | 1.86% |
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
CDW trades at $136.43, up 0.46% with mixed technical signals showing bearish overall momentum but bullish moving averages. The company reported strong Q2 2026 results with earnings beating estimates at $2.91 per share and revenue growth of 10% year-over-year, though margin compression remains a concern. Analyst consensus remains strongly bullish with 12 buy ratings and a $148.67 price target, representing 9% upside potential from current levels.
CDW benefits from strong AI infrastructure demand and consistent dividend payments, but faces margin pressure and CFO transition risks. The stock offers attractive valuation with P/E of 16.27 and P/S of 0.75, though high debt levels and competitive pressures warrant monitoring. Near-term catalysts include Q3 earnings and continued AI-driven infrastructure spending.
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →